120 related articles for article (PubMed ID: 15692602)
1. Liver iron concentration and fibrosis in a cohort of transfusion-dependent patients on long-term desferrioxamine therapy.
Berdoukas V; Bohane T; Tobias V; De Silva K; Fraser I; Aessopos A; Lindeman R
Hematol J; 2005; 5(7):572-8. PubMed ID: 15692602
[TBL] [Abstract][Full Text] [Related]
2. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Wu SF; Peng CT; Wu KH; Tsai CH
Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
[TBL] [Abstract][Full Text] [Related]
3. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.
Elalfy MS; Esmat G; Matter RM; Abdel Aziz HE; Massoud WA
Ann Hepatol; 2013; 12(1):54-61. PubMed ID: 23293194
[TBL] [Abstract][Full Text] [Related]
4. Thalassemia major between liver and heart: Where we are now.
Dessì C; Leoni G; Moi P; Danjou F; Follesa I; Foschini ML; Morittu M; Zappu A; Defraia E; Bina P; Cunico A; Civolani A; Podda RA; Origa R
Blood Cells Mol Dis; 2015 Jun; 55(1):82-8. PubMed ID: 25976473
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
[TBL] [Abstract][Full Text] [Related]
6. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
Deugnier Y; Turlin B; Ropert M; Cappellini MD; Porter JB; Giannone V; Zhang Y; Griffel L; Brissot P
Gastroenterology; 2011 Oct; 141(4):1202-11, 1211.e1-3. PubMed ID: 21741344
[TBL] [Abstract][Full Text] [Related]
7. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
[TBL] [Abstract][Full Text] [Related]
8. Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy.
Brown K; Subramony C; May W; Megason G; Liu H; Bishop P; Walker T; Nowicki MJ
J Pediatr Hematol Oncol; 2009 May; 31(5):309-12. PubMed ID: 19415007
[TBL] [Abstract][Full Text] [Related]
9. Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia.
Chen AC; Peng CT; Wu SF; Wu KH; Chiang IP; Tsai CH
Hemoglobin; 2006; 30(2):209-14. PubMed ID: 16798645
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
11. Lack of correlation between iron overload cardiac dysfunction and needle liver biopsy iron concentration.
Berdoukas V; Dakin C; Freema A; Fraser I; Aessopos A; Bohane T
Haematologica; 2005 May; 90(5):685-6. PubMed ID: 15921384
[TBL] [Abstract][Full Text] [Related]
12. Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia.
Risdon RA; Barry M; Flynn DM
J Pathol; 1975 Jun; 116(2):83-95. PubMed ID: 1151528
[TBL] [Abstract][Full Text] [Related]
13. Ferritin and LIC: predicting liver injury in children with sickle cell.
Smith E; Lebensburger J; Hilliard L; Kelly D; Fineberg N; Bai S; Howard T
J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):387-90. PubMed ID: 24553473
[TBL] [Abstract][Full Text] [Related]
14. Liver disease in transfusion dependent thalassaemia major.
Li CK; Chik KW; Lam CW; To KF; Yu SC; Lee V; Shing MM; Cheung AY; Yuen PM
Arch Dis Child; 2002 May; 86(5):344-7. PubMed ID: 11970927
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
16. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M
Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
[TBL] [Abstract][Full Text] [Related]
17. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases.
Prati D; Maggioni M; Milani S; Cerino M; Cianciulli P; Coggi G; Forni GL; Magnano C; Meo A; Gramignoli R; Rebulla P; Fiorelli G; Cappellini MD;
Haematologica; 2004 Oct; 89(10):1179-86. PubMed ID: 15477201
[TBL] [Abstract][Full Text] [Related]
18. Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
Tsironi M; Polonifi K; Deftereos S; Farmakis D; Andriopoulos P; Moyssakis I; Aessopos A
Eur J Haematol; 2005 Oct; 75(4):355-8. PubMed ID: 16146544
[TBL] [Abstract][Full Text] [Related]
19. Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT).
Maira D; Cassinerio E; Marcon A; Mancarella M; Fraquelli M; Pedrotti P; Cappellini MD
Ann Hematol; 2017 Nov; 96(11):1931-1936. PubMed ID: 28875336
[TBL] [Abstract][Full Text] [Related]
20. Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis C virus infection.
Hendy OM; Allam M; Allam A; Attia MH; El Taher S; Eldin MM; Ali A
Egypt J Immunol; 2010; 17(2):33-44. PubMed ID: 23082485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
